Commentary on "Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy" by D.C. Mastellos et al.
作者信息
de Miranda Santos Isabel Kinney Ferreira, de Barros Cardoso Cristina Ribeiro
机构信息
Department of Biochemistry and Immunology, Ribeirão Preto School of Medicine, University of São Paulo, Brazil.
Department of Clinical Analysis, Toxicology and Food Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
出版信息
Clin Immunol. 2021 Jan;222:108618. doi: 10.1016/j.clim.2020.108618. Epub 2020 Oct 27.
Abstract
摘要
相似文献
1
Commentary on "Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy" by D.C. Mastellos et al.
Clin Immunol. 2021 Jan;222:108618. doi: 10.1016/j.clim.2020.108618. Epub 2020 Oct 27.
2
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Clin Immunol. 2020 Nov;220:108598. doi: 10.1016/j.clim.2020.108598. Epub 2020 Sep 19.
3
Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition.
Blood. 2020 Oct 29;136(18):2080-2089. doi: 10.1182/blood.2020008248.
4
Response to "Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19".
Clin Immunol. 2021 Jan;222:108617. doi: 10.1016/j.clim.2020.108617. Epub 2020 Oct 25.
5
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.
Clin Immunol. 2020 Jun;215:108450. doi: 10.1016/j.clim.2020.108450. Epub 2020 Apr 29.
6
A double edged-sword - The Complement System during SARS-CoV-2 infection.
Life Sci. 2021 May 1;272:119245. doi: 10.1016/j.lfs.2021.119245. Epub 2021 Feb 17.
7
Is there relationship between SARS-CoV-2 and the complement C3 and C4?
Turk J Med Sci. 2020 Jun 23;50(4):687-688. doi: 10.3906/sag-2004-336.
8
Terminal complement inhibition dampens the inflammation during COVID-19.
Br J Haematol. 2020 Aug;190(3):e141-e143. doi: 10.1111/bjh.16916. Epub 2020 Jun 28.
9
Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Front Immunol. 2019 Jun 14;10:1157. doi: 10.3389/fimmu.2019.01157. eCollection 2019.
10
Serum Complement C3 and C4 and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression.
Front Immunol. 2021 Jun 7;12:696085. doi: 10.3389/fimmu.2021.696085. eCollection 2021.
本文引用的文献
1
Self-Reported Symptoms of COVID-19, Including Symptoms Most Predictive of SARS-CoV-2 Infection, Are Heritable.
Twin Res Hum Genet. 2020 Dec;23(6):316-321. doi: 10.1017/thg.2020.85.
2
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Clin Immunol. 2020 Nov;220:108598. doi: 10.1016/j.clim.2020.108598. Epub 2020 Sep 19.
3
Complement genes contribute sex-biased vulnerability in diverse disorders.
Nature. 2020 Jun;582(7813):577-581. doi: 10.1038/s41586-020-2277-x. Epub 2020 May 11.
4
Delirium in COVID-19: A case series and exploration of potential mechanisms for central nervous system involvement.
Gen Hosp Psychiatry. 2020 Jul-Aug;65:47-53. doi: 10.1016/j.genhosppsych.2020.05.008. Epub 2020 May 22.
5
Schizophrenia risk from complex variation of complement component 4.
Nature. 2016 Feb 11;530(7589):177-83. doi: 10.1038/nature16549. Epub 2016 Jan 27.
6
Delirium-biomarkers and genetic variance.
Front Pharmacol. 2014 Apr 16;5:75. doi: 10.3389/fphar.2014.00075. eCollection 2014.
7
Delirium epidemiology in critical care (DECCA): an international study.
Crit Care. 2010;14(6):R210. doi: 10.1186/cc9333. Epub 2010 Nov 23.
8
Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit.
JAMA. 2004 Apr 14;291(14):1753-62. doi: 10.1001/jama.291.14.1753.
9
Delirium and psychotic symptoms--an integrative model.
Med Hypotheses. 2002 Jan;58(1):24-7. doi: 10.1054/mehy.2001.1436.
10
The genetics of schizophrenia: a current, genetic-epidemiologic perspective.
Schizophr Bull. 1993;19(2):261-85. doi: 10.1093/schbul/19.2.261.
Zotero 插件